Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration

被引:107
|
作者
Roger, Emilie [3 ]
Lagarce, Frederic [1 ,2 ]
Benoit, Jean-Pierre [2 ]
机构
[1] INSERM, Lab Ingn Vectorisat Particulaire, IFR132, Bat IRIS,U646, F-49033 Angers, France
[2] CHU Angers, Angers, France
[3] Ethypharm, F-92213 St Cloud, France
关键词
Lipid nanocapsule; Sn38; Caco-2; Stability; Oral administration; Nanotechnology; SN-38-INCORPORATING POLYMERIC MICELLES; REVERSES MULTIDRUG-RESISTANCE; ACTIVE METABOLITE SN-38; DRUG-DELIVERY SYSTEM; DNA TOPOISOMERASE-I; LIQUID-CHROMATOGRAPHY; IRINOTECAN CPT-11; INTESTINAL-CELLS; CAMPTOTHECIN; NANOCARRIERS;
D O I
10.1016/j.ejpb.2011.01.021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this work was to encapsulate 7-Ethyl-10-hydroxy-camptothecin (Sn38) in lipid nanocapsules (LNCs) using phase inversion-based method in order to deliver Sn38 by oral route. LNCs were prepared by a low-energy emulsification method and were characterized for size, polydispersity index (PD!), surface charge, drug payload, in vitro drug release, and storage stability. Moreover, in view of an oral administration, in vitro stability in gastrointestinal fluid and permeability across Caco-2 cells were tested. Sn38-loaded LNCs with a mean particle size of 38 +/- 2 nm were obtained. The particles displayed a narrow size distribution and a drug payload of 0.40 +/- 0.07 mg/g of LNC dispersion. In vitro stability in simulated gastric and intestinal media was also observed. Finally, Sn38-loaded LNCs improved permeability of Sn38 across Caco-2 cells (5.69 +/- 0.87 x 10(6) cm s(-1) at 6 h vs 0.31 +/- 0.02 x 10(6) cm s(-1)) and intracellular concentration compared with free Sn38. In conclusion, Sn38 nanocarriers have been developed and display a strong potential for oral administration. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [21] Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
    Xing, Jing
    Zhang, Xiquan
    Wang, Zhe
    Zhang, Huanqing
    Chen, Peng
    Zhou, Gaoxin
    Sun, Chunlong
    Gu, Ning
    Ji, Min
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2019, 14 : 5201 - 5213
  • [22] Synthesis and In Vitro Anti-tumor Evaluation of Novel Glycoconjugated SN38 Derivatives
    Wang, Xin
    Yang, Chao
    Liao, Mengya
    Xie, Yongmei
    Yang, Jinliang
    CHEMISTRY LETTERS, 2023, 52 (10) : 788 - 790
  • [23] DDS-06E-A novel oral pH-sensitive micellar formulation of SN38: Effect of dosing regimen on efficacy and tolerability using a human colon xenograft model
    Le Garrec, Dorothee
    Benquet, Corinne
    Lessard, David
    Courtemanche, Lesley
    Palusova, Dana
    Kujawa, Piotr
    Bichat, Francis
    Raguin, Olivier
    Bari, Virginie
    Taga, Samir
    Smith, Damon
    CANCER RESEARCH, 2009, 69
  • [24] The effect of efflux pump inhibitors on in vitro and in vivo efficacy of solid lipid nanoparticles containing SN38
    Nasirizadeh, Samira
    Jaafari, Mahmoud Reza
    Iranshahi, Mehrdad
    Golmohammadzadeh, Shiva
    Mahmoudi, Asma
    Ansari, Legha
    Mosallaei, Navid
    Malaekeh-Nikouei, Bizhan
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 60
  • [25] DTS-108, a novel peptidic prodrug of SN38:: In vivo efficacy and toxicokinetic studies
    Meyer-Losic, Florence
    Nicolazzi, Celine
    Quinonero, Jerome
    Ribes, Fabien
    Michel, Matthieu
    Dubois, Vincent
    de Coupade, Catherine
    Boukaissi, Matthieu
    Chene, Anne-Sophie
    Tranchant, Isabelle
    Arranz, Valerie
    Zoubaa, Imane
    Fruchart, Jean-Sebastien
    Ravel, Denis
    Kearsey, Jonathan
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2145 - 2153
  • [26] Novel Topoisomerase 1 mutations in colorectal carcinoma cell lines are involved in SN38 resistance
    Gongora, C.
    Vie, N.
    Tuduri, S.
    Causse, A.
    Martineau, P.
    Pourquier, P. H.
    EJC SUPPLEMENTS, 2008, 6 (12): : 187 - 187
  • [27] Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: In vitro and in vivo studies
    Zhang, Hongfang
    Wang, Jinqiang
    Mao, Weiwei
    Huang, Jian
    Wu, Xianguo
    Shen, Youqing
    Sui, Meihua
    JOURNAL OF CONTROLLED RELEASE, 2013, 166 (02) : 147 - 158
  • [28] Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
    Wu, Chan
    Zhang, Yang
    Yang, Daoqiu
    Zhang, Jinfeng
    Ma, Juanjuan
    Cheng, Dan
    Chen, Jianming
    Deng, Li
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2019, 14 : 75 - 85
  • [29] The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
    Lin, Xue
    Stenvang, Jan
    Rasmussen, Mads Heilskov
    Zhu, Shida
    Jensen, Niels Frank
    Tarpgaard, Line S.
    Yang, Guangxia
    Belling, Kirstine
    Andersen, Claus Lindbjerg
    Li, Jian
    Bolund, Lars
    Brunner, Nils
    BMC GENOMICS, 2015, 16
  • [30] The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
    Xue Lin
    Jan Stenvang
    Mads Heilskov Rasmussen
    Shida Zhu
    Niels Frank Jensen
    Line S Tarpgaard
    Guangxia Yang
    Kirstine Belling
    Claus Lindbjerg Andersen
    Jian Li
    Lars Bolund
    Nils Brünner
    BMC Genomics, 16